Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics
Cyclophosphamide (Cy) is a prodrug that is mainly bioactivated by cytochrome P450 (CYP) 2B6 enzyme. Several other enzymes are also involved in its bioactivation and affect its kinetics. Previous studies have shown the effect of the enzymes’ genetic polymorphisms on Cy kinetics and its clinical outco...
Saved in:
Main Authors: | Ibrahim El-Serafi, Sinclair Steele |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-01-01
|
Series: | Advances in Pharmacological and Pharmaceutical Sciences |
Online Access: | http://dx.doi.org/10.1155/2024/4862706 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease
by: Sharon Cresci
Published: (2008-01-01) -
Analysis of depression in Brazil and the feasibility of incorporating pharmacogenomics as an auxiliary tool in antidepressant treatment
by: Rafaela Slaviero Pinheiro Cerdeira, et al.
Published: (2025-01-01) -
Cyclophosphamide: An Alternative Treatment in Crohn’s Disease
by: Gilles Lapointe, et al.
Published: (1989-01-01) -
Biological Properties, Bioactive Constituents, and Pharmacokinetics of Some Capsicum spp. and Capsaicinoids
by: Gaber, El-Saber Batiha, et al.
Published: (2023) -
Cyclophosphamide: An Overview
by: Aditya Kumar Bubna
Published: (2025-01-01)